Ident. | Authors (with country if any) | Title |
---|
000087 |
Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia Trenkwalder | AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. |
000304 |
Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Lévy [France] ; Eric Bardinet [France] ; Jérôme Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France] | Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom |
000314 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
000383 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
000404 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
000535 |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
000654 |
Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse] | Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease |
000672 |
J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse] | Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease |